AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 7449633 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg isosorbide dinitrate (10 subjects)
Number of subjects: 24
Study 7449633 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 mg prazosin (20 subjects)
Number of subjects: 24
Study 7449633 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg dihydralazine (8 subjects)
Number of subjects: 24
Study 31446423 — intervention group
Group type: EXPERIMENTAL
Intervention: Facebook ratings
Number of subjects: 0
Study 31446423 — intervention group
Group type: EXPERIMENTAL
Intervention: Facebook comments from unofficial sites
Number of subjects: 0
Study 31446423 — intervention group
Group type: EXPERIMENTAL
Intervention: Facebook comments from official sites
Number of subjects: 0
Study 31141099 — intervention group
Group type: EXPERIMENTAL
Intervention: Low socioeconomic status (L-SES)
Number of subjects: 9498
Study 31141099 — intervention group
Group type: EXPERIMENTAL
Intervention: Traumatic stressful events (TSEs)
Number of subjects: 9498
Study 27916286 — intervention group
Group type: EXPERIMENTAL
Intervention: Relating Therapy (RT)
Number of subjects: 29
Study 27916286 — intervention group
Group type: COMPARATOR
Intervention: Treatment as Usual (TAU)
Number of subjects: 29
Study 25846253 — intervention group
Group type: EXPERIMENTAL
Intervention: Verbascoside 100mg
Number of subjects: 100
Study 25846253 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 25846253 — intervention group
Group type: COMPARATOR
Intervention: Verbascoside 50mg
Number of subjects: 100
Study 23567399 — intervention group
Group type: EXPERIMENTAL
Intervention: Peaceful Mind intervention (up to 12 weekly in-home sessions and up to eight brief telephone sessions)
Number of subjects: 32
Study 23567399 — intervention group
Group type: EXPERIMENTAL
Intervention: Peaceful Mind intervention
Number of subjects: 32
Study 23567399 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 32
Study 22176903 — intervention group
Group type: EXPERIMENTAL
Intervention: Montelukast sodium (5 mg) for 12 weeks
Number of subjects: 60
Study 22176903 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 12 weeks
Number of subjects: 60
Study 19475468 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral infraorbital injections with 0.5% bupivacaine (Group IOB)
Number of subjects: 40
Study 19475468 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (Group NS)
Number of subjects: 40
Study 17429794 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovascular embolization
Number of subjects: 119
Study 17429794 — intervention group
Group type: COMPARATOR
Intervention: Surgical clipping
Number of subjects: 119
Study 17429794 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovascular embolization and Surgical clipping
Number of subjects: 119
Study 16937749 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketoprofen
Number of subjects: 40
Study 16937749 — intervention group
Group type: EXPERIMENTAL
Intervention: Nimesulide
Number of subjects: 40
Study 16937749 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetaminophen
Number of subjects: 40
Study 16937749 — intervention group
Group type: EXPERIMENTAL
Intervention: Tramadol
Number of subjects: 40
Study 16937749 — intervention group
Group type: EXPERIMENTAL
Intervention: Rofecoxib
Number of subjects: 40
Study 14597937 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormone therapy (conjugated estrogens and medroxyprogesterone)
Number of subjects: 0
Study 10400007 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin
Number of subjects: 62
Study 10400007 — intervention group
Group type: EXPERIMENTAL
Intervention: Ifetroban
Number of subjects: 62
Study 10400007 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril + Aspirin
Number of subjects: 62
Study 10400007 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril + Ifetroban
Number of subjects: 62
Study 10400007 — intervention group
Group type: COMPARATOR
Intervention: Enalapril + Placebo
Number of subjects: 62
Study 7767151 — intervention group
Group type: EXPERIMENTAL
Intervention: Acyclovir (800 mg by mouth daily)
Number of subjects: 74
Study 7767151 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 74
Study 2179492 — intervention group
Group type: EXPERIMENTAL
Intervention: External fixator
Number of subjects: 0
Study 2179492 — intervention group
Group type: COMPARATOR
Intervention: Plaster cast immobilization
Number of subjects: 0
Study 7271091 — intervention group
Group type: EXPERIMENTAL
Intervention: Minocycline 100 mg once daily for 7 days
Number of subjects: 289
Study 7271091 — intervention group
Group type: EXPERIMENTAL
Intervention: Minocycline 100 mg once daily for 21 days
Number of subjects: 289
Study 7271091 — intervention group
Group type: EXPERIMENTAL
Intervention: Men with initial Chlamydia trachomatis infection
Number of subjects: 289
Study 7271091 — intervention group
Group type: EXPERIMENTAL
Intervention: Men without C. trachomatis infection
Number of subjects: 289
Study 31201476 — intervention group
Group type: EXPERIMENTAL
Intervention: Dopamine receptor agonist, pramipexole 0.5 mg
Number of subjects: 18
Study 31201476 — intervention group
Group type: EXPERIMENTAL
Intervention: Dopamine receptor antagonist, amisulpride 400 mg
Number of subjects: 18
Study 31201476 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 28352928 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate plus micronutrients (Group B)
Number of subjects: 30
Study 28352928 — intervention group
Group type: COMPARATOR
Intervention: Methotrexate only (Group A)
Number of subjects: 30
Study 25245858 — intervention group
Group type: EXPERIMENTAL
Intervention: Fine bore NGT
Number of subjects: 15
Study 25245858 — intervention group
Group type: EXPERIMENTAL
Intervention: Fine bore NGT and Wide bore NGT
Number of subjects: 15
Study 25245858 — intervention group
Group type: COMPARATOR
Intervention: No NGT (control)
Number of subjects: 15
Study 23179103 — intervention group
Group type: EXPERIMENTAL
Intervention: High beta-palmitate (HBP) formula (43% of palmitic acid at sn-2, n = 30)
Number of subjects: 83
Study 23179103 — intervention group
Group type: COMPARATOR
Intervention: Regular formula with low-beta palmitate (LBP) (14% of palmitic acid at sn-2, n = 28)
Number of subjects: 83
Study 23179103 — intervention group
Group type: COMPARATOR
Intervention: Breast-fed infants (n = 25)
Number of subjects: 83
Study 21915551 — intervention group
Group type: EXPERIMENTAL
Intervention: Total hip arthroplasty in patients with hepatitis C
Number of subjects: 71
Study 21915551 — intervention group
Group type: COMPARATOR
Intervention: Total hip arthroplasty in control group
Number of subjects: 71
Study 21915551 — intervention group
Group type: EXPERIMENTAL
Intervention: Total knee arthroplasty in patients with hepatitis C
Number of subjects: 71
Study 21915551 — intervention group
Group type: COMPARATOR
Intervention: Total knee arthroplasty in control group
Number of subjects: 71
Study 21915551 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined hepatitis-C group
Number of subjects: 71
Study 18443258 — intervention group
Group type: EXPERIMENTAL
Intervention: ACEIs or angiotensin receptor blockers
Number of subjects: 1094
Study 18443258 — intervention group
Group type: EXPERIMENTAL
Intervention: ACEIs to a BP lower than 130/80 mm Hg
Number of subjects: 1094
Study 16555143 — intervention group
Group type: EXPERIMENTAL
Intervention: Early Risers 'Skills for Success' conduct problems prevention program
Number of subjects: 0
Study 16555143 — intervention group
Group type: COMPARATOR
Intervention: No-intervention comparison group
Number of subjects: 0
Study 14666764 — intervention group
Group type: EXPERIMENTAL
Intervention: Xiehuo Yangyin powder (XHYY) plus methimazole
Number of subjects: 60
Study 14666764 — intervention group
Group type: COMPARATOR
Intervention: Methimazole alone
Number of subjects: 60
Study 10973545 — intervention group
Group type: EXPERIMENTAL
Intervention: Tepid cardiopulmonary bypass (34 degrees C)
Number of subjects: 31
Study 10973545 — intervention group
Group type: COMPARATOR
Intervention: Hypothermic cardiopulmonary bypass (28 degrees C)
Number of subjects: 31
Study 10973545 — intervention group
Group type: EXPERIMENTAL
Intervention: Not applicable
Number of subjects: 31
Study 8844718 — intervention group
Group type: EXPERIMENTAL
Intervention: Fructo-oligosaccharides (FOS) 12.5 g/day
Number of subjects: 20
Study 8844718 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saccharose)
Number of subjects: 20
Study 1739571 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine 2 mg kg‐1 with adrenaline 1 in 200,000 plus hyaluronidase 3000 iu
Number of subjects: 22
Study 1739571 — intervention group
Group type: COMPARATOR
Intervention: Bupivacaine 2 mg kg‐1 with adrenaline 1 in 200,000 without hyaluronidase
Number of subjects: 22
Study 6371788 — intervention group
Group type: EXPERIMENTAL
Intervention: Zaditen syrup
Number of subjects: 60
Study 6371788 — intervention group
Group type: COMPARATOR
Intervention: Clemastine
Number of subjects: 60
Study 31764361 — intervention group
Group type: EXPERIMENTAL
Intervention: AquaVac system (low-cost NPWT)
Number of subjects: 36
Study 31764361 — intervention group
Group type: COMPARATOR
Intervention: VAC ATS system (commercial NPWT)
Number of subjects: 36
Study 31764361 — intervention group
Group type: EXPERIMENTAL
Intervention: Both systems
Number of subjects: 36
Study 29908031 — intervention group
Group type: EXPERIMENTAL
Intervention: Curcumin
Number of subjects: 90
Study 29908031 — intervention group
Group type: COMPARATOR
Intervention: Mefenamic acid (Control)
Number of subjects: 90
Study 26630423 — intervention group
Group type: EXPERIMENTAL
Intervention: Stratified group intervention (STarT Back)
Number of subjects: 583
Study 26630423 — intervention group
Group type: EXPERIMENTAL
Intervention: High-risk stratified group
Number of subjects: 583
Study 26630423 — intervention group
Group type: EXPERIMENTAL
Intervention: Medium-risk stratified intervention
Number of subjects: 583
Study 26630423 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-risk stratified patients
Number of subjects: 583
Study 26630423 — intervention group
Group type: COMPARATOR
Intervention: Historical control (generic group intervention)
Number of subjects: 583
Study 24561494 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg daily pravastatin
Number of subjects: 9014
Study 24561494 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9014
Study 22322521 — intervention group
Group type: EXPERIMENTAL
Intervention: Articaine (40 mg with Epinephrine 0.5 mg %)
Number of subjects: 10
Study 22322521 — intervention group
Group type: EXPERIMENTAL
Intervention: Articaine (40 mg with Epinephrine 1 mg %)
Number of subjects: 10
Study 22322521 — intervention group
Group type: COMPARATOR
Intervention: Mepivacaine (30 mg with Epinephrine 1 mg %)
Number of subjects: 10
Study 22322521 — intervention group
Group type: COMPARATOR
Intervention: Mepivacaine (20 mg with Epinephrine 1 mg %)
Number of subjects: 10
Study 20850004 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous artesunate 2·4 mg/kg at 0, 12, and 24 hours, then daily
Number of subjects: 66
Study 20850004 — intervention group
Group type: COMPARATOR
Intervention: Intravenous quinine 20mg/kg initially then 10mg/kg three times a day
Number of subjects: 66
Study 17550648 — intervention group
Group type: EXPERIMENTAL
Intervention: Diethylcarbamazine (DEC) alone (6 mg/kg)
Number of subjects: 82
Study 17550648 — intervention group
Group type: EXPERIMENTAL
Intervention: Diethylcarbamazine (DEC) combined with Albendazole (ALB) (400 mg)
Number of subjects: 82
Study 17550648 — intervention group
Group type: COMPARATOR
Intervention: Control group (DEC alone)
Number of subjects: 82
Study 15370010 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone 50 mg daily, with daily dispensing for the first 7 days and weekly dispensing for the following 11 weeks
Number of subjects: 97
Study 11372045 — intervention group
Group type: EXPERIMENTAL
Intervention: PGV (cisplatin 50 mg/m², gemcitabine 1000 mg/m², vinorelbine 25 mg/m²)
Number of subjects: 343
Study 11372045 — intervention group
Group type: EXPERIMENTAL
Intervention: PGT (cisplatin 50 mg/m², gemcitabine 1000 mg/m², paclitaxel 125 mg/m²)
Number of subjects: 343
Study 11372045 — intervention group
Group type: COMPARATOR
Intervention: PG (cisplatin 100 mg/m², gemcitabine 1000 mg/m²)
Number of subjects: 343
Study 9215189 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg vaginal prostaglandin E2 gel
Number of subjects: 83
Study 9215189 — intervention group
Group type: COMPARATOR
Intervention: 0.5 mg intracervical prostaglandin E2 gel
Number of subjects: 83
Study 8433883 — intervention group
Group type: EXPERIMENTAL
Intervention: MCT formula (38% medium-chain fatty acids)
Number of subjects: 18
Study 8433883 — intervention group
Group type: COMPARATOR
Intervention: LCT formula (6% medium-chain fatty acids)
Number of subjects: 18
Study 3659138 — intervention group
Group type: EXPERIMENTAL
Intervention: Knee extensor muscle torque tracings
Number of subjects: 30
Study 29693214 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcutaneous vagus nerve stimulation (tVNS)
Number of subjects: 0
Study 29693214 — intervention group
Group type: COMPARATOR
Intervention: Neutral sham stimulation
Number of subjects: 0
Study 25405463 — intervention group
Group type: EXPERIMENTAL
Intervention: Airtraq laryngoscope
Number of subjects: 30
Study 25405463 — intervention group
Group type: COMPARATOR
Intervention: Macintosh laryngoscope
Number of subjects: 30
Study 25500488 — intervention group
Group type: EXPERIMENTAL
Intervention: Liposomal curcumin (10 - 400 mg/m2)
Number of subjects: 50
Study 25500488 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 25500488 — intervention group
Group type: EXPERIMENTAL
Intervention: Liposomal curcumin (≥ 120 mg/m2)
Number of subjects: 50
Study 25500488 — intervention group
Group type: EXPERIMENTAL
Intervention: Liposomal curcumin (up to 120 mg/m2)
Number of subjects: 50
Study 23810616 — intervention group
Group type: EXPERIMENTAL
Intervention: Free fibula flap
Number of subjects: 34
Study 23810616 — intervention group
Group type: COMPARATOR
Intervention: Deep circumflex iliac artery (DCIA) flap
Number of subjects: 34
Study 20965846 — intervention group
Group type: EXPERIMENTAL
Intervention: PDLLA screws
Number of subjects: 58
Study 20965846 — intervention group
Group type: COMPARATOR
Intervention: Titanium metallic screws
Number of subjects: 58
Study 18514162 — intervention group
Group type: EXPERIMENTAL
Intervention: NaF
Number of subjects: 10
Study 18514162 — intervention group
Group type: EXPERIMENTAL
Intervention: H(2)SiF(6)
Number of subjects: 10
Study 18514162 — intervention group
Group type: EXPERIMENTAL
Intervention: Natural fluoride
Number of subjects: 10
Study 18514162 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.67 mg/L solution
Number of subjects: 10
Study 18514162 — intervention group
Group type: EXPERIMENTAL
Intervention: 5.45 mg/L solution
Number of subjects: 10
Study 16817039 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclic etidronate therapy (oral regimen repeated every 14 weeks)
Number of subjects: 31
Study 16817039 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 31
Study 16817039 — intervention group
Group type: COMPARATOR
Intervention: Comparison between etidronate and placebo groups
Number of subjects: 31
Study 12798892 — intervention group
Group type: EXPERIMENTAL
Intervention: TENS device applied on the patient's abdomen before and during office hysteroscopy (group A, n = 71)
Number of subjects: 142
Study 12798892 — intervention group
Group type: COMPARATOR
Intervention: No TENS device used (control group B, n = 71)
Number of subjects: 142
Study 12798892 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 142
Study 10618952 — intervention group
Group type: EXPERIMENTAL
Intervention: Saline dilution (20% with 0.9% saline, 1 ml)
Number of subjects: 20
Study 10618952 — intervention group
Group type: COMPARATOR
Intervention: Control (no dilution)
Number of subjects: 20
Study 10618952 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin (375 mg daily for 3 days)
Number of subjects: 20
Study 7488989 — intervention group
Group type: EXPERIMENTAL
Intervention: Soft-splint
Number of subjects: 30
Study 7488989 — intervention group
Group type: EXPERIMENTAL
Intervention: Palliative-treatment
Number of subjects: 30
Study 7488989 — intervention group
Group type: COMPARATOR
Intervention: No-treatment
Number of subjects: 30
Study 1903558 — intervention group
Group type: EXPERIMENTAL
Intervention: misoprostol, 400 micrograms twice daily
Number of subjects: 15
Study 1903558 — intervention group
Group type: COMPARATOR
Intervention: high‐dose liquid antacid regimen
Number of subjects: 15
Study 7079249 — intervention group
Group type: EXPERIMENTAL
Intervention: Graduated filters
Number of subjects: 0
Study 7079249 — intervention group
Group type: COMPARATOR
Intervention: Placebo filters
Number of subjects: 0
Study 7079249 — intervention group
Group type: COMPARATOR
Intervention: Quit smoking on own
Number of subjects: 0
Study 7079249 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term quitters
Number of subjects: 0
Study 7079249 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuing smokers
Number of subjects: 0
Study 30131043 — intervention group
Group type: COMPARATOR
Intervention: Dual-chamber pacing (DDDR)
Number of subjects: 74
Study 30131043 — intervention group
Group type: EXPERIMENTAL
Intervention: Algorithms of minimization of right ventricular pacing (MRVP)
Number of subjects: 74
Study 27722224 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate post-extractive ultra-wide 7 mm-diameter implants (group A)
Number of subjects: 24
Study 27722224 — intervention group
Group type: COMPARATOR
Intervention: Delayed implant installation 4 months after tooth extraction and socket preservation (group B)
Number of subjects: 24
Study 24767716 — intervention group
Group type: EXPERIMENTAL
Intervention: Individuals who reported at least one burn injury (3.98% of the population, 145 out of 3645 individuals)
Number of subjects: 3645
Study 24767716 — intervention group
Group type: EXPERIMENTAL
Intervention: Individuals with burns seeking care from a traditional healer (21%, 30 out of 145 individuals)
Number of subjects: 3645
Study 23095376 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture plus usual care
Number of subjects: 233
Study 23095376 — intervention group
Group type: COMPARATOR
Intervention: Usual care alone
Number of subjects: 233
Study 20336635 — intervention group
Group type: EXPERIMENTAL
Intervention: Estrogen‐plus‐progestin therapy (CHT)
Number of subjects: 2502
Study 20336635 — intervention group
Group type: EXPERIMENTAL
Intervention: Estrogen therapy (ET)
Number of subjects: 2502
Study 20336635 — intervention group
Group type: EXPERIMENTAL
Intervention: Any use of CHT
Number of subjects: 2502
Study 20336635 — intervention group
Group type: EXPERIMENTAL
Intervention: Any use of ET
Number of subjects: 2502
Study 20336635 — intervention group
Group type: COMPARATOR
Intervention: Control group (non-users of HT)
Number of subjects: 2502
Study 20336635 — intervention group
Group type: EXPERIMENTAL
Intervention: Case group (HT users)
Number of subjects: 2502
Study 18550943 — intervention group
Group type: EXPERIMENTAL
Intervention: Depth jump training
Number of subjects: 31
Study 18550943 — intervention group
Group type: EXPERIMENTAL
Intervention: VertiMax training
Number of subjects: 31
Study 18550943 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 31
Study 16028129 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic vaccines (ALVAC-HIV [vCP1452] or ALVAC-HIV and Remune)
Number of subjects: 79
Study 16028129 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 79
Study 11796648 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine (150 mg)
Number of subjects: 24
Study 11796648 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine (75 mg)
Number of subjects: 24
Study 11796648 — intervention group
Group type: EXPERIMENTAL
Intervention: Famotidine (10 mg)
Number of subjects: 24
Study 11796648 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 10233334 — intervention group
Group type: EXPERIMENTAL
Intervention: Salicylic acid (SA) 5% in ethanol applied in a chamber for 4 hours on acetone-treated skin
Number of subjects: 18
Study 10233334 — intervention group
Group type: EXPERIMENTAL
Intervention: Salicylic acid (SA) 5% in ethanol applied in a chamber for 4 hours on mild dermatitis (1% SLS)
Number of subjects: 18
Study 10233334 — intervention group
Group type: EXPERIMENTAL
Intervention: Salicylic acid (SA) 5% in ethanol applied in a chamber for 4 hours on severe dermatitis (2% SLS)
Number of subjects: 18
Study 10233334 — intervention group
Group type: EXPERIMENTAL
Intervention: Salicylic acid (SA) 5% in ethanol applied in a chamber for 4 hours on tape stripped skin
Number of subjects: 18
Study 10233334 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation of SA penetration with TEWL measurements
Number of subjects: 18
Study 10233334 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation of SA penetration with erythema measurements
Number of subjects: 18
Study 7749166 — intervention group
Group type: EXPERIMENTAL
Intervention: Navoban (tropisetron) 5 mg once daily
Number of subjects: 1072
Study 7749166 — intervention group
Group type: EXPERIMENTAL
Intervention: Navoban (tropisetron) 10 mg once daily
Number of subjects: 1072
Study 7749166 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone (Day 1, 0.2 mg/kg i.v.; Days 2-6, 8 mg p.o.)
Number of subjects: 1072
Study 7749166 — intervention group
Group type: EXPERIMENTAL
Intervention: Alizapride (Day 1, 100 mg i.v. and 4 x 50 mg p.o.; Days 2-6, 4 x 5 mg p.o.)
Number of subjects: 1072
Study 7749166 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1072
Study 1968783 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg esmolol IV
Number of subjects: 45
Study 1968783 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg esmolol IV
Number of subjects: 45
Study 1968783 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study 6152977 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone undecanoate (TU)
Number of subjects: 26
Study 6152977 — intervention group
Group type: COMPARATOR
Intervention: Mesterolone (M)
Number of subjects: 26
Study 6139042 — intervention group
Group type: EXPERIMENTAL
Intervention: Vecuronium (0.1 mg/kg)
Number of subjects: 0
Study 6139042 — intervention group
Group type: EXPERIMENTAL
Intervention: Vecuronium
Number of subjects: 0
Study 6139042 — intervention group
Group type: COMPARATOR
Intervention: Pancuronium (0.1 mg/kg)
Number of subjects: 0
Study 6139042 — intervention group
Group type: COMPARATOR
Intervention: Pancuronium
Number of subjects: 0
Study 31340853 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard printed patient information materials with access to a multimedia information resource
Number of subjects: 0
Study 31340853 — intervention group
Group type: COMPARATOR
Intervention: Standard printed patient information materials alone
Number of subjects: 0